Search Results

Jubilant HollisterStier received a warning letter over problems that the FDA said necessitate an immediate and comprehensive assessment of the contract manufacturing organization’s global operations.

Jubilant DraxImage Inc., dba Jubilant Radiopharma, a wholly-owned subsidiary of Jubilant Pharma Limited, has entered into an exclusive partnership with Cardiac Imaging, Inc., of Oakbrook Terrace, Illinois, to provide a daily-leased rubidium solution to healthcare facilities interested in performing cardiac PET.

Jubilant DraxImage Inc., dba Jubilant Radiopharma, a wholly-owned subsidiary of Jubilant Pharma Limited, is pleased to announce the clearance by the FDA to use its RUBY Rubidium Elution System™ and RUBY-FILL® in mobile settings.

Jubilant Draximage Inc. and Evergreen Theragnostics, Inc announced a new agreement for Jubilant’s radiopharmacy business to prepare, sell, and distribute doses of OCTEVY™ (Kit for Preparation of Ga 68 DOTATOC Injection) to positron emission tomography (PET) customers across the US. OCTEVYTM is pending approval by the United States Food & Drug Administration (FDA), which is expected in 2H 2023.

Jubilant Therapeutics’ differentiated, orally bioavailable molecules address both validated and novel therapeutic targets in oncology and immunology.

Jubilant Radiopharma’s Radiopharmacies division is excited to announce an investment of $50 million (USD) to expand its PET radiopharmaceutical manufacturing facilities by adding six (6) sites in strategic locations throughout the United States.

Jubilant Therapeutics Inc. announced the appointment of Nadir Patel as an independent director on the Company’s Board of Directors.